Image: Vivoo

Vivoo, the wellness app known for at-home urine tests, has announced a new suite of products at CES 2025, including reproductive health tests and an enhanced smart toilet system.

The company is introducing three new hormone tests that track FSH, LH, and hCG levels to help users monitor fertility windows and early stages of pregnancy. Using deep learning image processing technology, the tests display results in the Vivoo app seconds after urination, offering what the company describes as unmatched cycle-tracking accuracy compared to software-only solutions.

“As a team consisting of over 70% women in our early 30s, the development of Vivoo’s reproductive hormone tests is deeply personal to us,” said Miray Tayfun, Co-founder and CEO of Vivoo. “We designed these tests in response to the real challenges we as individuals faced with regard to our reproductive health. Fertility is a growing global crisis, and during the development, many of us uncovered critical insights, some even made the life-changing decision to freeze their eggs.”

“The trio of tests are vital tools to help women truly understand their bodies—pinpointing ovulation, tracking cycles, and providing actionable insights about fertility and vaginal health. Our mission is to empower women to make confident, informed choices, whether planning for children, choosing not to, or simply seeking a deeper connection with their health. Vivoo is here to support every step of their journeys.”

The reproductive health kits will be available during Q1 2025, with same-day or next-day delivery through Amazon and other channels.

Additionally, Vivoo unveiled a second iteration of its smart toilet, which measures hydration levels through urine gravity. The device, designed for easy installation on existing toilet bowls, will be available to businesses in Q4 2025 and consumers in Q1 2026, starting at $29.99 per month with a yearly commitment.

The company is also launching an at-home erythrocyte sedimentation rate (ESR) test in Q4 2025 to help users track inflammation levels and make informed lifestyle changes.

Vivoo currently has over 300,000 users across more than 50 countries and offers 11 different at-home tests. The company is backed by investors including Draper Associates, Otsuka Pharmaceuticals, 500 Startups, Techstars, and Halogen Ventures.

Show CommentsClose Comments

Leave a comment